Moderna (MRNA) fundamentals: P/E, valuation, undervalued?
Moderna · Health Care · ref. ETF XLV · price $142.77
In short — Moderna trades at —× earnings (P/E), -30.6× forward, with a net margin of -141.4 % and revenue growth of +2 %. Read: Not (yet) profitable (valued on growth, not earnings).
Is Moderna stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$142.77+483.4% over range
Aug 28, 25low $22.36 · high $174.38Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
17% recommend buying · 12 analysts
Valuation : Not (yet) profitable — valued on growth, not earnings
Valuation
—
P/E (price/earnings)
-30.6
Forward P/E
—
PEG
8.4
Price/book (P/B)
$57.0B
Market cap
-7.61
EPS
Profitability & growth
-141.4 %
Net margin
+2 %
Revenue growth
—
Earnings growth
$1.3B
Total debt
Moderna income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $19.3B | $8.4B | 43.4 % |
| 2023 | $6.8B | $-4.7B | -68.8 % |
| 2024 | $3.2B | $-3.6B | -110.0 % |
| 2025 | $1.9B | $-2.8B | -145.2 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Moderna's P/E and is the stock undervalued? What's a good P/E?
Moderna's P/E is — (forward -30.6). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Not (yet) profitable".
Is Moderna profitable?
Moderna has a net margin of -141.4 % (EPS -7.61). The company is not (yet) profitable.
Is MRNA stock expensive?
Our read: "Not (yet) profitable" — valued on growth, not earnings. Cross-check with growth and sector.
💬 A question about Moderna? The JPI assistant answers using our backtest data.